GEO DataSets

Analysis of FFPE core biopsies from pre-treated patients with HER2+ breast cancer (BC) randomized to receive neoadjuvant chemotherapy only or chemotherapy+trastuzumab (herceptin). Results provide insight into the molecular basis of survival outcomes following trastuzumab-based chemotherapy.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 2 genotype/variation, 2 other, 2 protocol sets

Platform:

GPL570

Series:

GSE50948

156 Samples

Download data: CEL

(Submitter supplied) These data can be used for evaluation of the clinical utility of the research-based PAM50 subtype predictor in predicting pathological complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. The NeOAdjuvant Herceptin [NOAH] trial demonstrated that trastuzumab significantly improves pCR rates and 3-year event-free survival (EFS) in combination with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with HER2+ breast cancer.

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS5027

Platform:

GPL570

156 Samples

Download data: CEL

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array; Genome variation profiling by SNP array

Platforms:

GPL6801 GPL570

156 Samples

Download data: CEL, CNCHP

(Submitter supplied) Results: In subjects who completed treatment and surgery, the pCR and near-complete response rates were 15.8% in HER2-negative and 50% in HER2-positive subjects. When stratified by genomic subtype, subjects of the HER2-enriched subtype had the best response (66.7%), the luminal A (11%) and B (4.8%) subtypes the poorest. Of 147 patients tested for p53 mutations using the AmpliChip test, 78 variants were detected; 55 were missense. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL5325

158 Samples

Download data

(Submitter supplied) Tumor core biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the 03-311 trial. Gene expression profiling was conducted on these tumor biopsies to identify signatures of response to preoperative therapy. This study was initiated to identify biomarkers of response to preoperative trastuzumab-conotaining therapy. We performed transcriptional profiling of patient tumor biopsies obtained at baseline and post brief-exposure to trastuzumab to test the hypothesis that transcriptional changes upon brief-exposure to therapy can provide an early readout of subsequent response.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6947

100 Samples

Download data: IDAT, TXT

(Submitter supplied) CALGB 40601 was activated as a 3-arm study (paclitaxel + trastuzumab + lapatinib [THL], paclitaxel + trastuzumab [TH] and paclitaxel + lapatinib [TL]). In December 2010, twoneoadjuvant studies were presented at the Cancer Therapy and Research Center-American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium that affected the scientific and practical enthusiasm for the TL arm. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platforms:

GPL11154 GPL16791

265 Samples

Download data: TSV, TXT, XLS